Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on December 3, 2008
Japanese Journal of Clinical Oncology 2009 39(2):81-85; doi:10.1093/jjco/hyn130
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/2/81    most recent
hyn130v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hsieh, W.-C.
Right arrow Articles by Lee, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsieh, W.-C.
Right arrow Articles by Lee, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer

Wei-Chung Hsieh1,5, Ya-Wen Cheng1,3, Cuei-Jyuan Lin2, Ming-Chih Chou3,6, Chih-Yi Chen4 and Huei Lee2,3

1 Institute of Medicine, Chung Shan Medical University, Taichung
2 Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung
3 Lung Cancer Research Center, Chung Shan Medical University, Taichung
4 Department of Surgery, China Medical University, Taichung, Taiwan, Republic of China
5 Department of Internal Medicine, Da Chien General Hospital, Miaoli
6 Department of Surgery, Chung Shan Medical University, Taichung

For reprints and all correspondence: Huei Lee, Lung Cancer Research Center, Institute of Medical and Molecular Toxicology, Chung Shan Medical University, No. 110, Sec. 2, Chien-Kuo N. Rd., Taichung, Taiwan, Republic of China

Received July 31, 2008; accepted October 21, 2008

Objective: A novel T-77C polymorphism in the promoter region of the DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. Here, we attempt to clarify: (i) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (ii) whether this polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients.

Methods: A total of 294 primary lung cancer patients and 288 potential controls were recruited into our study. Clinical data were collected. The genotypes of XRCC1 T-77C were identified by polymerase chain reaction.

Results: Our case–control study showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed that patients with TT had a lower survival rate than those with the TC + CC genotype (33.1% versus 48.8%, P = 0.031). The Cox regression analysis further indicated that patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95% CI, 1.16–2.86, P = 0.008).

Conclusion: Our results suggest that XRCC1 T-77C variants (TC + CC) may act as a favorable prognostic indicator of resected NSCLC.

Key Words: XRCC1 genetic polymorphism • NSCLC • prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.